Serum levels and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies;Stȩzenie w surowicy oraz wydalanie z moczem rozpuszczalnych Fas (sFas) u chorych z pierwotnymi glomerulopatiami

Polskie Archiwum Medycyny Wewnetrznej

Volumn 108, Issue 3, 2002, Pages 843-847

  Kacprzyk, Feliks ^a,b  

^a Klinika Nefrologiczna Instytutu M   (Poland)

^b Klinika Nefrologii AM   (Poland)

Author keywords

Glomerulonephritis; Immunosuppressive treatment; Serum and urinary soluble Fas

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; SOLUBILITY; TIME; TREATMENT OUTCOME; URINE;

ADULT; AGED; ANTIGENS, CD95; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; SOLUBILITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036769642     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Lorz C., Ortiz A., Justo P. i wsp.: Proapoptic Fas ligand is expressed by normal kidney tubular epithelum and injured glomeruli. Am. Soc. Nephrol., 2000, 11, 1266.
2. Ortiz A., Lorz C., Egido J.: New kids in the block: the role of FasL and Fas in kidney damage. J. Nephrol., 1999, 12, 150.
3. Shou I., Tashiro K., Kurusii A. i wsp.: Serum levels of soluble Fas and disease activity in patients with IgA nephropathy. Nephron, 1999, 81, 387.
4. Sano H., Asano K., Minatoguchi S. i wsp.: Plasma soluble fas and soluble fas ligand in chronic glomerulonephrits. Nephron, 1998, 80, 153.
5. Ortiz A., Lorz C., Egido J.: The Fas ligand/Fas system in renal injury, Nephrol. Dial. Transplant., 1999, 14; 1831.